Medizone International — Investor Presentation (June 2017)
30 slides from Medizone International's investor presentation, Jun 22, 2017
Slide 1: Medizone International Investor Update – June 21, 2017
AsepticSure® Medizone International, Inc.Investor Update – June 21, 2017 1 June 21, 2017 – 4:00 – 5:00 PM ESTToll free for North America: 1-800-681-1924Toll call outside North America: 1-303-223-4393A recording of the call will be available from 6/21/17-6/28/17:1-800-633-8284 Conference ID: 21854308
Slide 2: Safe Harbor Statement
Safe Harbor Statement This investor update contains forward looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Our actual results could differ materially from those projected in these forward-looking statements, which involve a
Slide 3: Agenda
Agenda Company overviewThe Problem – The SolutionCommercial Strategy UpdateFinancialsQuestion & AnswerClosing comments 3 Investor Update 6/21/17
Slide 4: Executive Summary
Executive Summary Medizone International (OTCQB:MZEI) Company formed in 1986 to develop treatments for lipid enveloped virus like Hepatitis B & C and HIV/AIDSStrategic shift in 2007 to develop a disinfectant system capable of addressing a wide range of applications to minimize the transmission of di
Slide 5: The Problem
The Problem Reducing the transmission of disease remains a global health priorityHealthcare facilities110% of inpatients in the U.S. contract infections from the hospital room that is manually cleaned.HAIs are the 4th leading cause of death in the U.S. and cost over $40B a year.Recent survey of hosp
Slide 6: Limits of current cleaning and disinfection technologies
Standard cleaningTime consuming, labor intensive and costlyProven ineffective and inconsistent Current technologies have limited impact 6 UV TechnologyShadow effect impacts efficacyLack of regulatory approved efficacy claims Ozone TechnologyHigh levels (500+ PPM) needed to achieve necessary kill rat
Slide 7: The Solution - The AsepticSure System
7 The Solution - The AsepticSure System Ease of use in a wide range of applications The Science of Synergy EPA validated disinfectant process: AsepticSure produced consistent kill rates across 160 runs using a nominal 1.4% Hydrogen peroxide mixture combined with 80 ppm of OzonePeer reviewed/publishe
Slide 8: Strategic Intent and Commercial Priorities
Strategic Intent: Establish AsepticSure as a superior solution worldwide to achieve unprecedented kill rates of bacteria and viral pathogens in a wide range of commercial applications including healthcare, biodefense, and public health preparednessCommercial Priorities:Regulatory ApprovalManufacturi
Slide 9: Regulatory Status
Regulatory StatusApprovals: United States (EPA), Canada, New Zealand and ChileEPA approval (Nov 2016): AsepticSure Ozone Generator™ fogging system is for use in hospitals, clinics, food industry, sporting venues, and hotels to disinfect hard non-porous surfaces.AsepticSure Oxidative Catalyst is for
Slide 10: FDA Communications
Thursday April 6, 2017 teleconference513(g) submission made on May 17, 2017 Expected response within 60 daysHighlights from the submission:Request for “confirmation that the company’s AsepticSure® (“AsepticSure® System” or the “system”) is not considered a medical device when used for general hospit
Slide 11: Manufacturing
Contract manufacturing support established with CogmedixCurrent FDA and EPA registered manufacturer Establishment registration number has been received by EPAPrepared to manufacture AsepticSure Generation III systemsRecent international electrical safety standards approval is being incorporated into
Slide 12: Addressable Markets
Addressable MarketsMarketing and sales process Technical support and customer service 3) Commercial Execution 12 Investor Update 6/21/17
Slide 13: Addressable Markets
Healthcare industryHealthcare waste exposureBio-Terrorism countermeasuresPublic health preparednessBuilding remediation Addressable Markets 13 Investor Update 6/21/17
Slide 14: The AsepticSure Difference in Healthcare
EPA registered disinfectant systemUS regulatory confirmation of disinfectant claimsCombination of oxidative compounds (O3 and H202) produces a unique mixture of free radicals with oxidation potential much higher than Ozone or Hydrogen Peroxide aloneHospital spaces and other public facilities can eff
Slide 15: AsepticSure Efficacy: Am J Infection Control 2011
Efficacy testing across a wide range of pathogens including spores (C. difficile and B. subtilis)Testing occurred in test chamber and full-size laboratory room/hospital room AsepticSure Efficacy: Am J Infection Control 2011 15 1. Am J Infect Control 2011;39:873-879: Effectiveness of a novel ozone-ba
Slide 16: Response to Emerging Pathogens: Klebsiella pneumoniae
16 Response to Emerging Pathogens Klebsiella pneumonia is becoming more prevalent in many hospitals and because of its increasing antibiotic resistance it is very dangerousEfficacy tests against Klebsiella pneumoniaeCarbapenemase-resistant strain and β-lactamase resistant strain.Classified an ESKAPE
Slide 17: AsepticSure Efficacy: The Funeral Home Study
Objectives: (A) Access potential microbiological contamination in a local funeral services mortuary (B) Conduct a pre-treatment and post-treatment assessment of AsepticSure.Process:All pretreatment surface sampling (May 9 and May 12, 2017) and treatment (May 19) were performed in the preparation roo
Slide 18: The Funeral Home Study: Results
Pre-treatment assessments showed significant bacterial growth in multiple locations. Plates that showed growth exhibited a variety of organisms with no one organism being predominant.Post treatment assessments showed zero growth in all locations assessed after 24h, while one bacterial colony was pre
Slide 19: AsepticSure Efficacy: Athletic Equipment
Objective: (A) Access potential microbiological contamination in routinely used sports equipment (ice hockey equipment) (B) Conduct a pre-treatment and post-treatment assessment of AsepticSure.Process:All surface sampling, treatment and microbiology work (swab plating, incubation and identification)
Slide 20: Athletic Equipment Study: Results
Pre-treatment assessments showed significant bacterial growth on all sports equipment items. Pre-treatment samples showed growth with a variety of organisms; no one organism being predominant.Post treatment assessments showed zero growth on all locations for all items assessed after 24hConclusion:A
Slide 21: Bio-Terrorism Countermeasures: Anthrax
United States Patent No. 8,636,951 – Bio-terrorism Counteraction Using Ozone and Hydrogen Peroxide (Jan 2014)Europe: Patent No. 252583B - Bio-Terrorism Counter Measures Using Ozone and Hydrogen Peroxide (June 2016)AsepticSure demonstrated bacterial spore efficacy for Anthrax surrogateB. subtilis is
Slide 22: Global Public Health: Ebola, SARS, MERS
Viral efficacy studies conducted with the National Research Council-Canada (NRC Human Health Therapeutics Portfolio)Two viruses were identified by the NRC as test organisms: Adenovirus (PTG3602)Coronavirus, transmissible gastroenteritis virus (TGEV) ATCC# VR-763Allows assessment of both enveloped an
Slide 23: Building Remediation
Active research and development program based on initial successful trialsOverall reduction in bacterial load Mold Smoke Methamphetamine residueResidual effects from water damage Building Remediation 23 Investor Update 6/21/17 Building Remediation
Slide 24: Marketing and Sales Process
Lead generation:Leverage existing relationships developed by the Medizone teamUtilization of key suppliers as “commissioned” lead generatorsInvestor/shareholder relationships to support leadsTrade show attendance Social media and traditional media outreachResources:Utilize existing media content, AJ
Slide 25: Marketing and Sales Process (continued)
Hospital market:Targeted implementation of Product Evaluation Program (PEP)Place instrument, consumables and service/supportPost 3-6 month demonstration, transition to purchase contractPublish resultsExpand key opinion leader network through PEP successesDefense and Public Health markets:Demonstrati
Slide 26: Technical Support and Customer Service
Medizone team in Canada can handle initial product salesOn-site training and support program to address most customersMost technical support issues can be handled remotelyDispatch support to customer as neededOptions to scale technical support and customer service:Success based expansion with placem
Slide 27: Intellectual Property
4) Intellectual Property Canada: Patent No. 2735739 – Healthcare Facility Disinfection Process and System with Oxygen/Ozone (Nov. 2011)United States: Patent No. 8,551,399 – Healthcare Facility Disinfecting System (Oct 2013). Patent No. 8,636,951 – Bio-Terrorism Counteraction Using Ozone and Hydrogen
Slide 28: Financials
Prior budgets supported through exempt private placements of equitySecure Near Term FinancingContinue with private equity offerings in the near termPreferred stock offering with strategic partnersEMA Partners outreach: Focused on securing a development, commercialization, and/or licensing partner Fi
Slide 29: Agenda
Agenda Company overviewThe Problem – The SolutionCommercial Strategy UpdateFinancialsQuestion & AnswerClosing comments 29 Investor Update 6/21/17
Slide 30: Summary and Closing Comments
Investor Update 6/21/17 30 Summary and Closing Comments Reducing the transmission of disease remains a global health priorityAsepticSure is well positioned to be a superior solution worldwide within healthcare, biodefense, and public health functionsMedizone is continuing to expand the commercial ca
Medizone International — Investor Presentation (June 2017) on 6ix